DOME GOLD MINES LTD

0.200

+0.000

Volume:- -

Turnover:- -

Market Cap:79.29M

PE:-32.79

High:0.200

Open:0.200

Low:0.200

Close:0.200

Loading ...

Overview Company News Filings

Concept

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Dome Gold Mines Confident of Government Approval for Dredging Plan at Fiji Project

MT Newswires Live

·

30 Jan

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/DME.AU"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"DME.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DME.AU\",,,,,undefined,":{"symbol":"DME.AU","market":"AU","secType":"STK","nameCN":"DOME GOLD MINES LTD","latestPrice":0.2,"timestamp":1746079920000,"preClose":0.2,"halted":0,"volume":0,"delay":0,"nameEN":"DOME GOLD MINES LTD","floatShares":163554730,"shares":396428660,"eps":-0.0061,"marketStatus":"Closed","change":0,"latestTime":"05-01 16:12:00 AEST","open":0.2,"high":0.2,"low":0.2,"amount":0,"amplitude":0,"askPrice":0.2,"askSize":49497,"bidPrice":0.053,"bidSize":9471,"shortable":3,"etf":0,"ttmEps":-0.0061,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1746144000000},"marketStatusCode":5,"adr":0,"exchange":"ASX","adjPreClose":0.2,"openAndCloseTimeList":[[1746057600000,1746079200000]],"volumeRatio":0,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DME.AU\",,,,,undefined,":{"symbol":"DME.AU","floatShares":163554730,"roa":"-3.61%","roe":"-6.28%","lyrEps":-0.0061,"shares":396428660,"dividePrice":0,"high":0.2,"amplitude":0,"preClose":0.2,"low":0.2,"week52Low":0.1,"pbRate":"2.12","psRate":"-3171429.28","week52High":0.2,"institutionHeld":0,"latestPrice":0.2,"committee":-0.678775,"eps":-0.0061,"divideRate":0,"volume":0,"delay":0,"ttmEps":-0.0061,"open":0.2,"prevYearClose":0.2,"prevWeekClose":0.18,"prevMonthClose":0.2,"prevQuarterClose":0.18,"fiveDayClose":0.18,"twentyDayClose":0.18,"sixtyDayClose":0.175},"@#url:\"https://hq.skytigris.cn/market/plate/belongs/DME.AU\",params:#limit:6,delay:false,,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"DME.AU\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2507161348","title":"Dome Gold Mines Confident of Government Approval for Dredging Plan at Fiji Project","url":"https://stock-news.laohu8.com/highlight/detail?id=2507161348","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507161348?lang=en_us&edition=fundamental","pubTime":"2025-01-30 13:59","pubTimestamp":1738216745,"startTime":"0","endTime":"0","summary":"Dome Gold Mines Ltd  said that it was confident that its dredging plan at the Sigatoka River project will receive final approval from the Fijian government, according to a Thursday filing with the Australian bourse.The company's unit, Magma Mines, has been selected to operate the government's emergency desilting program, the filing said.While Dome has met all the project requirements, the company needs to obtain approval from fishing rights holders, who are expected to experience minimal impact from the dredging operations, the filing added.A meeting with fishing rights holders and government officials is scheduled for February, the filing added.Given the recent flooding along the Sigatoka River and government support, Dome remains confident that the final approvals will be granted, allowing the dredging plan to proceed, the company said.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["DME.AU","BK7095"],"gpt_icon":0},{"id":"2504679921","title":"S&P 500 Gains and Losses Today: UnitedHealth Stock Ails as Results Fall Short","url":"https://stock-news.laohu8.com/highlight/detail?id=2504679921","media":"Investopedia","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504679921?lang=en_us&edition=fundamental","pubTime":"2025-01-17 06:21","pubTimestamp":1737066099,"startTime":"0","endTime":"0","summary":"Major U.S. equities indexes ticked lower on Thursday, failing to gain ground a day after soft inflation data and an upbeat start to earnings season helped drive a strong rally.The S&P 500 slipped 0.2%, ending a streak of three straight positive trading sessions. The Dow was also down 0.2%, while the tech-heavy Nasdaq Composite fell 0.9%.UnitedHealth Group  shares dropped 6.0%, posting the heaviest daily loss in the S&P 500, following the healthcare giant's first earnings release since last month's fatal shooting of insurance unit chief Brian Thompson. Although quarterly profits came in ahead of expectations, UnitedHealth reported lower-than-expected revenue. An increase in medical costs also contributed to a year-over-year uptick in the firm's medical cost ratio, which compares medical expenses to total revenue.Shares of US Bancorp  plunged 5.6%. The move lower came after the financial services firm reported mixed quarterly results, topping adjusted profit estimates but falling short o","market":"sg","thumbnail":"https://www.investopedia.com/thmb/2fOrFEjBI35Sc7RQHC9rwW29Mys=/5500x3772/filters:no_upscale():max_bytes(150000):strip_icc()/GettyImages-2187619704-70ee5b2156784a439f82bea1cc961a33.jpg","type":0,"news_type":0,"thumbnails":["https://www.investopedia.com/thmb/2fOrFEjBI35Sc7RQHC9rwW29Mys=/5500x3772/filters:no_upscale():max_bytes(150000):strip_icc()/GettyImages-2187619704-70ee5b2156784a439f82bea1cc961a33.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.investopedia.com/s-and-p-500-gains-and-losses-today-unitedhealth-stock-ails-as-results-fall-short-8775572","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"investopedia_highlight","symbols":["LU0314104364.USD","LU1720051017.SGD","LU0868494708.USD","LU2129689514.USD","LU0345774391.USD","ESmain","SSO","SG9999011175.SGD","LU2244417387.USD","VOO","TXN","DME.AU","OEX","LU1670627923.USD","IE0004086264.USD","LU0690374615.EUR","LU2023250843.SGD","LU1496350502.SGD","SG9999001176.SGD","LU0011850046.USD","LU2413666699.HKD","03145","BK4519","LU0082616367.USD","LU0823414478.USD","LU0109391861.USD","LU1291159041.SGD","LRCX","LU1815336760.USD","SPY","UPRO","LU0384037296.USD","OEF","LU0683600562.USD","SPXU","AMAT","KLAC","SDS","DXCM","LU0965509101.SGD","SH","LU0347712357.USD",".SPX","IVV","LU1868838027.USD","TSM","LU2054465674.USD","USB","UNH","EL"],"gpt_icon":1},{"id":"2503674082","title":"Why this speculative ASX stock could rocket 70%","url":"https://stock-news.laohu8.com/highlight/detail?id=2503674082","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503674082?lang=en_us&edition=fundamental","pubTime":"2025-01-16 04:15","pubTimestamp":1736972100,"startTime":"0","endTime":"0","summary":"Investors with a high tolerance for risk might want to take a look at the speculative ASX stock in this article. After all, the team at Bell Potter believes that it could deliver big returns for investors over the next 12 months if everything goes to plan. Which speculative ASX stock?The stock in question is Opthea Ltd . It is a biopharmaceutical company developing novel therapies that aim to address the unmet needs in the treatment of highly prevalent and progressive retinal diseases. This includes wet age-related macular degeneration  and diabetic macular edema . Opthea's lead product candidate is sozinibercept. It is being evaluated in two fully enrolled pivotal Phase 3 clinical trials  for use in combination with standard-of-care anti-VEGF-A therapies. The trial aims to improve the overall efficacy and deliver superior vision gains compared to standard-of-care anti-VEGF-A agents alone. What is the broker saying?","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/01/16/why-this-speculative-asx-stock-could-rocket-70/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["LU0823421333.USD","OPT.AU","BK4529","LU1989764664.SGD","BK4512","BK4573","BK4585","LU1242518931.SGD","LU1880398554.USD","LU2360106780.USD","LU1242518857.USD","LU0823434583.USD","LU2054465674.USD","LU2264538146.SGD","LU0823421416.USD","LU0823434740.USD","GFS","BK7508","IE0009356076.USD","LU1880398471.USD","LU0719512351.SGD","BK4588","LU1951198990.SGD","BK4532","LU1988902786.USD","LU2458330243.SGD","LU0642271901.SGD","LU1064131342.USD","BK7067","OPT","LU0390134368.USD","LU0082616367.USD","IE00B5949003.HKD","LU2458330169.SGD","LU0056508442.USD","LU2250418816.HKD","LU1803068979.SGD","LU0127658192.USD","LU0109392836.USD","BK4575","LU1303367103.USD","LU1316542783.SGD","LU1951200564.SGD","LU0889565833.HKD","BK4139","BK4543","DME.AU","BK4141","IE0004445239.USD"],"gpt_icon":1},{"id":"2501245417","title":"Biotech smallcap Opthea eyes 5% jump as key drug of interest validated in paper","url":"https://stock-news.laohu8.com/highlight/detail?id=2501245417","media":"The Market Herald","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501245417?lang=en_us&edition=fundamental","pubTime":"2025-01-07 11:09","pubTimestamp":1736219340,"startTime":"0","endTime":"0","summary":"Dual ASX and NASDAQ listed Opthea Ltd  has jumped 4.5% to 77cps today after having its diabetic eye drug of interest further validated as a potential treatment in a scientific paper.Treating Diabetic Macular Edema  – a condition associated with diabetes that is sight-threatening where blood vessels leak fluid – is among Opthea’s key goals, using the drug sozinibercept.According to a presentation on the company’s website , the drug represents a “multibillion-dollar” opportunity.The drug is a “first-in-class” protein-based compound that combines different naturally occurring proteins in specific combinations intended to target key areas of the body. In this case, the eye, where affected by DME.The reason shares were climbing on Tuesday was the drug appears to have been partially validated in a paper published in the peer-reviewed journal Translational Vision Science & Technology this week.The material provided in this article is for information only and should not be treated as investmen","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/biotech-smallcap-opthea-eyes-5-jump-as-key-drug-of-interest-validated-in-paper-2025-01-07/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["BK4141","DME.AU","LU0823434740.USD","LU2250418816.HKD","BK7508","LU0390134368.USD","BK4532","LU0979878070.USD","LU1242518857.USD","LU1880398471.USD","LU2054465674.USD","LU0642271901.SGD","LU1880398554.USD","LU2360106780.USD","BK4512","BK4575","AMD","BK7095","LU0082616367.USD","LU0109392836.USD","LU0719512351.SGD","LU1316542783.SGD","BK4554","LU1989764664.SGD","IE00BMPRXR70.SGD","LU0823421416.USD","IE0004445239.USD","GFS","LU2458330243.SGD","IE0009356076.USD","IE00B5949003.HKD","BK4573","LU0056508442.USD","LU1852331112.SGD","BK4529","BK4588","IE00BMPRXN33.USD","BK4566","LU2098885051.SGD","BK4534","LU1242518931.SGD","OPT.AU","LU0198837287.USD","LU0823434583.USD","BK4139","LU1951198990.SGD","OPT","LU1303367103.USD","LU0823421333.USD","LU1988902786.USD"],"gpt_icon":1}],"pageSize":4,"totalPage":4,"pageCount":1,"totalSize":14,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/DME.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"DME.AU\",market:\"AU\",,,undefined,":[]}}